Treatment of secondary hyperparathyroidism in hemodialysis patients With the development of dialysis technology, patient survival has been significantly prolonged and the prevalence of secondary hyperparathyroidism has increased. Secondary hyperparathyroidism leads to disorders of mineral metabolism and high blood phosphorus is an important risk factor for patient death. Treatment of secondary hyperparathyroidism: Medications Treatment medications include: (1) active vitamin D, such as osteopontinol, alfa osteopontinol; (2) non-calcium, non-aluminum phosphorus binding agents, such as lanthanum carbonate; (3) non-high calcium VD derivatives, such as paricalcitol, doxorubicin; and (4) calcium-sensitive receptor agonists, such as cenacaser. Cinacalcet improves the prognosis and quality of survival of dialysis patients and usually needs to be combined with an active vitamin D receptor agonist. Surgical treatment The KDIGO guideline indications for parathyroidectomy are: severe secondary hyperparathyroidism in CKD stages 3-5, where drug therapy has failed, and parathyroidectomy should be performed.